Is GSK seeking first-line FDA approval for Jideytro in lung cancer?

Yes. The article says GSK is preparing a first-line FDA push for Jideytro in lung cancer, describing it as the company’s first lung cancer drug and saying the filing is backed by an “unprecedented complete response rate.” However, no trial details, timing, patient population, or numerical results were disclosed.